DH 29  Development of analytical methods DH 30  Analysis of EU market products DH 33  Development of a novel tablet DH 36  Preparation of study medication.

Slides:



Advertisements
Similar presentations
 AUTHOR- Musiba Baliruno Denis, B.pharm (MUST) SUPERVISORS ;  Prof. K.A.M. Kuria, PhD - Department of Pharmaceutics and Pharmacy Practice, University.
Advertisements

Annual Product Review (APR) Product Quality Review (PQR)
5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
Manufacturing Process
Standard Welcome to CHEM. & PHARM. CO., LTD. ˙Sincerity ˙Honesty
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Reference, Retention and Reserve Samples
MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.
Regulatory requirements and benefits converting to Continued Process Verification.
Nutraceuticals The Road Ahead
WP9: Project management
SCAMPI Review WP6: Project Management 3r d Annual Review of Project CNET-ICT Beaulieu, Brussels, Belgium 26 November, 2013.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. THE PRACTICE OF REGULATORY INTELLIGENCE: CASE STUDIES OMICS 5 th International Pharmaceutical.
Case studies Saila Antila, PhD WHO consultant Training workshop on Pharmaceutical Quality, Good Manufacturing Practice & Bioequivalence, Kiev
Improved Tablet  Focus on stability  Focus on reasonable production  Focus on packaging material High-End Tablet  Vision?! Study Medication  Focus.
Beijing, 4th ALLIUM Symposium, April 2004 G&H Influence of environmental and genetic factors on the alliin content of garlic bulbs - Odile Huchette INRA,
Quality control Lecture 1.
WP1 Management. N° of work package: 1 Management Duration in months: 36+2 EGEC Description of the tasks: 1.1. Project Management (EGEC) Coordination in.
Agenda Introduction/presentations (5 min each) Overview of ENVIROPAK project (Prof John Taylor, UP) (20 min) Technical Annex (10 min each WP leader) –reviewing.
Garlic & Health a European initiative for the development of high quality garlic and its influence on biomarkers of atherosclerosis and cancer in humans.
 Objectives / Deliverables  Strategy  Ideas  First Results  Recent and Next Steps G&H Meeting th April, 2002 Leipzig, Germany WP 7 Pharmaceutics.
Institute for Reference Materials and Measurements (IRMM) Geel, Belgium 1 Update on Activities of the.
Rolf Gebhardt University of Leipzig Medical Fakulty Institute of Biochemistry EU-Project: Garlic & Health Effects of High Quality Garlic on Markers of.
Study Medication  Time schedule  Résumé Development of an improved tablet formulation  Long term stability  Reasonable production conditions  Focus.
1 G&H Meeting 4-5 th October, 2001 G&H Meeting 4-5 th October, 2001 Wellesbourne, UK Wellesbourne, UK WP 7 Pharmaceutics WP 7 Pharmaceutics Objectives.
Odile Huchette, research engineer Christèle Bellamy, research technician Didier Perrin, research assistant G&H October 2002, Montpellier WP3 / cultivation,
Examples of deficiencies in submitted data Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October.
Extracts from garlic dry powders modulate LPS-induced liberation of cytokines. H.-P. Keiß 1, V.M. Dirsch 1, T. Hartung 2, A.M. Vollmar 1 1 Department of.
ABOUT OUR NEW HPLC METHOD  We have identified a new compound in garlic HPLC profile, the S-allyl cystein (SAC) that has a potential therapeutic activity.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
The Interaction of Garlic With Mediators of Inflammation Prof. A. M. Vollmar Dr. V. M. Dirsch H - P Keiß.
Core Indicators during Latvia Iruma Kravale Head of Strategic Planning Unit, European Union Funds Strategy Department, Ministry of Finance DG.
Solid dosage forms Tablets
Suad Y. Alkarib 1 Dina Elraih 2 Waddah F. Nour 3.
 Objectives Improved Tablet  focus on stability  focus on low costs High-End Tablet  maximum dose  controlled release G&H Meeting 1-2 October, 2002.
Quality Assurance of Medicines under Universal Health Coverage Program by Siriwat Tiptaradol (Presenter) Duangporn Abhigantaphand Sooksri Ungboriboonpisal.
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Analytical Method Validation Under Good Laboratory Practices (GLPs) Webinar Details Date : September 02 nd Friday 2016 Time : 01:00PM ET / 10:00AM PT Duration:
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
About Symbiosis Online Publishing
HOLD-TIME STUDIES.
Rapid HPTLC method for the detection of adulteration in dietary supplements with synthetic drugs Tiên DO.
WP3 - Evaluation and proposal selection
UNISEC Universal Influenza Vaccines Secured
Physico-chemical Control of Dosage Forms
- Pharmaceutical Equivalence Study
Oral Dosage of Drugs Chapter 10 MAT 119.
Introduction of Biopharmaceutics & Pharmacokinetics
Solid dosage forms Tablets
New Issue Released by Journal of Analytical Techniques - Volume 3 - Issue 1 – 2017
The Interaction of Garlic With Mediators of Inflammation
Industrial Pharmacy.
701 Passez une bonne journée et un bon week-end !
Table 1. Formulation of gluten-free cake
Firdaus | Sofia | Nurainiza | Hafizah
HHV ⁵014 NUTRACEUTICAL FORMULATION TECHNOLOGY
Update Interim implementation report and financial statement (December 2006) request from the Commission for additional documents in February –
GMP Inspection Process
Objectives… G&H Meeting February, 2003 Liverpool, UK
Practical Pharmaceutical Orientation
Tablet coating T.SHIVAKUMAR B.PHARMACY
VICH Guidelines on stability: OVERVIEW
Palais des Nations, Geneva
David Wright Professor of Pharmacy practice University of East Anglia
Fourteen (28%) of 50 patients met the criteria of nonresponse with test results of over 52 AU. Patient 1 received a second full loading dose of 300 mg.
VICH Guidelines on stability: OVERVIEW
Research, 2016, Vol. 4, No. 6, doi: /jfnr-4-6-2
Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after.
Presentation transcript:

DH 29  Development of analytical methods DH 30  Analysis of EU market products DH 33  Development of a novel tablet DH 36  Preparation of study medication DH 31,32,34,35  Publication/Patents (Dissemination) G&H Meeting Jan , 2003 Leiden, The Netherlands WP 7 Pharmaceutics (Lichtwer Pharma)  Objectives…

 Overall analytical method for garlic

 Garlic under enzyme inhibiting conditions Retention time [min] Absorption (AU) 1 Alliin 2 unknown (Allylcysteine) 3  -Glutamyl-S-allylcysteine 4  -Glutamyl-S-trans-1-propenylcysteine 5  -Glutamyl phenylalanine

 Garlic under aqueous conditions

 Quality of EU garlic products

 Stability of EU garlic products

Garlic of the future! Jungle of the market

Details on Stability Studies Organic film based  Full compliance to ICH-guidelines  Up to seven different packaging materials  Two different dosage forms Aqueous film based  Reformulation of tablet core  Formulation of coating  Establishing aqueous coating procedure

Organic Film Tablets (100 mg)

Organic Film Tablets (300 mg)

 For the organic coated tablets real time stability according EU guidelines are available for 30 – 36 months (4 time improvement!)  For aqueous coated tablets real time stability according EU guidelines are available for 1 – 5 months (ongoing studies!)  Conclusion Novel Tablet (Stability)

 A EU drug application procedure will be done when 6 months of real time stability data for the 300 mg tablets are available (3rd quarter of 2004)  A 100 mg tablet will be developed within the next 6 months according to the 300 mg one  Outlook Dissemination Novel Tablet (Aqueous Coating)

 TablettingMinor difficulties with the flowability and compressibility of the EU garlic powder  CoatingEverything went fine…  Sugar CoatingEverything went fine…  Release Full compliance with specifications!  GCP Minor deviations  Study Medication for the Human Intervention Study - Résumé …

 Publication (Dissemination)  Auger J and Haffner T et al. Congress for Hyphenated Technologies in Chromatography, February , Bruges, Belgium)  Keiss H-P, Dirsch V, Hartung T, Haffner T, Truemann L, Auger J, Kahane R. and Vollmar A M. J. Nutrition 133(7), (2003)  Arnault, I, Christidès, J P, Mandon, N, Haffner, T, Kahane, R and Auger Journal of Chromatography A, 2003 Mar 28;991(1):69-75  Siess M-H, Haffner T et al.. J Agric Food Chem 51, (2003)  Le Bon A-M, Vernevaut M.-F., Vernevaut L G., Kahane R., Auger, J., Haffner T., Siess, M.-H.. S Submitted for publication  Auger J and Haffner T et al. Congress for Hyphenated Technologies in Chromatography, February , Bruges, Belgium)  Keiss H-P, Dirsch V, Hartung T, Haffner T, Truemann L, Auger J, Kahane R. and Vollmar A M. J. Nutrition 133(7), (2003)  Arnault, I, Christidès, J P, Mandon, N, Haffner, T, Kahane, R and Auger Journal of Chromatography A, 2003 Mar 28;991(1):69-75  Siess M-H, Haffner T et al.. J Agric Food Chem 51, (2003)  Le Bon A-M, Vernevaut M.-F., Vernevaut L G., Kahane R., Auger, J., Haffner T., Siess, M.-H.. S Submitted for publication

Many thanks to Marie-Hélène, Verena, Angelika, Ingrid, Anne-Marie, Jacques, and Hans-Peter… …for covering my Achilles heel heel – the publication work!

Who is a Cesar without his… Who is a Cesar without his… A Nobody ! Wolfgang Lüdeke José Galan-Sousa Silvia Striegl Anke Wermann & Anja Müller Anke Wermann & Anja Müller

Bianca Beutke Stability Coordination Bianca Beutke Stability Coordination Cleopatra?!

Thank you very much! I will miss you!